Apr 25, 2014 by Dan CarrollWhy This Huge Dividend Stock Has Snoozed Through 2014Pfizer's trailed behind fellow Dow members Johnson & Johnson and Merck year to date with meager gains in 2014, but can this tried-and-true big pharma giant turn things around?
Apr 25, 2014 by Dan CarrollVisa's Downbeat Outlook Assists the Dow's 160-Point SlideMicrosoft goes flat despite an upbeat earnings report and sealing its buy of Nokia's device business.
Apr 24, 2014 by Dan CarrollIllumina, Inc.: How the Market's Smartest Company is Living Up to the HypeIllumina won rave reviews for its innovative technology after making the $1,000 genome possible, but the company showed off its financial prowess in the first quarter.
Apr 24, 2014 by Dan CarrollWhy Investors Should Love Biogen's Earnings MissBiogen's shares slumbered through trading after the company's earnings release, but Tecfidera's impressive growth makes the future impressively bright for this biotech giant.
Apr 24, 2014 by Dan Carroll3M, Verizon Earnings Misses Take Down the DowDespite a great day from Caterpillar, the blue-chip index falls on a day full of earnings reports.
Apr 24, 2014 by Dan CarrollIs This Struggling Drugmaker Worth $100 Billion?After AstraZeneca reportedly rebuffed Pfizer's huge acquisition offer, we look into what makes the former's pipeline attractive to Pfizer and investors.
Apr 23, 2014 by Dan CarrollWill These 3 Dividend Stocks Impress Investors This Earnings Season?Bristol-Myers Squibb, Merck, and Pfizer all face challenges in their coming earnings releases. Will these stocks live up to expectations?
Apr 23, 2014 by Dan Carroll3 Reasons Celgene Will Bounce Back This YearCelgene's stock has suffered with biotech's fall this year, but this top health-care stock's poised for long-term success.
Apr 23, 2014 by Dan Carroll3 Things You Need to Watch For in Boston Scientific's EarningsBoston Scientific's stock has surged as of late, but can shares keep up their rally with earnings season at hand?
Apr 22, 2014 by Dan CarrollMcDonald's Miss Can't Shake the Dow's 100-Point JumpHome Depot's upgrade helps the stock jump by 2.4%, while Netflix's subscription boom powers the stock's surge.
Apr 21, 2014 by Dan CarrollPfizer's Missed Megadeal Sparks the Dow's RisePfizer may have struck out in its bid to buy AstraZeneca, but the Big Pharma stock's 2% jump leads a good day for the market.
Apr 17, 2014 by Dan CarrollUnitedHealth, GE Earnings Pull the Dow in Opposite DirectionsA big day for blue-chip earnings sees IBM and UnitedHealth's stocks take a plunge.
Apr 17, 2014 by Dan CarrollWill Merck & Co. Inc Unseat Biotech's Hottest Drug?Gilead Sciences' oral hepatitis C drug Sovaldi has taken the market by storm, but Merck's looking to fight back in the race to capture this lucrative niche.
Apr 16, 2014 by Dan CarrollIs Johnson & Johnson's Dividend Unbeatable?Johnson & Johnson sports a solid dividend, but is it the right pick for your portfolio?
Apr 16, 2014 by Dan CarrollIntel's Falling Earnings Can't Keep the Dow from a Triple-Digit SurgeUnitedHealth tumbles hard after Citi downgrades the stock.
Apr 16, 2014 by Dan CarrollCan Edwards Lifesciences Corp. Capitalize on This Opportunity?Edwards wins a legal ruling against Medtronic, but while momentum's behind this stock, don't be overconfident.
Apr 15, 2014 by Dan CarrollDow Fights Back Into the Green on Good Coke, J&J NumbersThe Dow Jones claws out of the red on a strong day from Coca-Cola and Johnson & Johnson.
Apr 14, 2014 by Dan CarrollVisa, Intel Power the Dow's JumpCitigroup's stock bounces after company earnings top analyst expectations despite big revenue declines in mortgage lending and bond trading.
Apr 11, 2014 by Dan CarrollJPMorgan's Earnings Disaster Drops the Dow 100 PointsWells Fargo's own earnings hit and Merck's strong showing can't save the markets from a downbeat day.
Apr 10, 2014 by Dan CarrollDow Hits a Triple-Digit Slump Behind JPMorgan's Pre-Earnings PlungeChevron also falls on a downbeat day from the markets.
